Holen Sie sich die Stockscreener-App
3.20
1.84%
-0.06
Handel nachbörslich:
3.32
0.12
+3.75%
Schlusskurs vom Vortag:
$3.26
Offen:
$3.22
24-Stunden-Volumen:
124.44K
Relative Volume:
0.08
Marktkapitalisierung:
$2.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.85M
KGV:
-0.4785
EPS:
-6.6877
Netto-Cashflow:
$-8.00M
1W Leistung:
+0.95%
1M Leistung:
+5.26%
6M Leistung:
-69.87%
1J Leistung:
-89.90%
1-Tages-Spanne:
$3.15
$3.27
1-Wochen-Bereich:
$3.15
$3.5996
52-Wochen-Spanne:
$2.75
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
3.20 | 2.54M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Is Alzamend Neuro Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
What analysts say about Alzamend Neuro Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
Alzamend Neuro Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
What drives NextNav Inc. Equity Warrant stock priceAccelerated earnings growth - Autocar Professional
Is NVIDIA Corporation a good long term investmentFree Risk Assessment Services - jammulinksnews.com
LMND.WS Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com
What drives SIFCO Industries Inc. stock priceFree Stock Market Trend Analysis - jammulinksnews.com
What analysts say about DLR.PRK stockHigh-velocity gains - jammulinksnews.com
What drives BETRW stock priceConsistently high yield - jammulinksnews.com
Is Gildan Activewear Inc. a good long term investmentTremendous gains - jammulinksnews.com
What drives Alzamend Neuro Inc. stock priceConsistently high returns - jammulinksnews.com
What institutions are buying Alzamend Neuro Inc. stock nowPortfolio Boosting Stock Alerts - Newser
How Alzamend Neuro Inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser
Why Alzamend Neuro Inc. stock attracts strong analyst attentionMassive Upside Selection - Newser
What makes Alzamend Neuro Inc. stock price move sharplyReliable Low Risk Signals - Newser
Alzamend Neuro (NASDAQ:ALZN) Trading Down 2% – Should You Sell? - Defense World
Alzamend Neuro Stock: A Green Day Hiding Red Flags for Traders - thekhabrilal
Alzamend Neuro (ALZN) Secures $5 Million in Private Placement | - GuruFocus
Fast-Tracked: $5M Investment Accelerates 5 Phase II Trials for Alzheimer's and Mental Health Breakthroughs - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen - Defense World
Alzamend Neuro Soars 11.29% Post Reverse Split - AInvest
Citadel Advisors LLC Makes New Investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Growth in Short Interest - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 18.6% in May - Defense World
Why Alzamend Neuro (ALZN.O) Plunged 30% – A Liquidity Crisis or Hidden Catalyst? - AInvest
Promising Pharmaceutical Stocks To Follow Today – May 29th - Defense World
Unraveling Alzamend Neuro's 30% Plunge: A Liquidity Crisis or Sector Sell-Off? - AInvest
Lithium Stocks To Consider – May 29th - Defense World
Alzamend Neuro begins phase II trial for novel lithium delivery system By Investing.com - Investing.com South Africa
Alzamend Neuro doses first patient in Phase II study of AL001 - TipRanks
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | - GuruFocus
Sector Update: Health Care - marketscreener.com
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Asianet Newsable
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled By Stocktwits - Investing.com India
Lithium Stocks To ConsiderMay 29th - MarketBeat
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone - Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - Benzinga
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):